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advanced stage cancer.[4] Patients with hypercalcemia 
of malignancy tend to have limited survival of several 
months, and it is not clear whether this poor prognosis is 
related to the advanced stage of malignancy associated 
hypercalcemia or just simply a marker of underlying 
cancer.[5]
It is unclear whether asymptomatic hypercalcemia 
heralds the later development of cancer. To answer this 
question, Hamilton et al. retrospectively analyzed the 
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Abstract
Hypercalcemia of  malignancy is a common finding typically found in patients with advanced stage cancers. We aimed to provide an 
updated review on the etiology, pathogenesis, clinical presentation, and management of  malignancy-related hypercalcemia. We searched 
PubMed/Medline, Scopus, Embase, and Web of  Science for original articles, case reports, and case series articles focused on hypercalcemia 
of  malignancy published from 1950 to December 2014. Hypercalcemia of  malignancy usually presents with markedly elevated calcium 
levels and therefore, usually severely symptomatic. Several major mechanisms are responsible for the development of  hypercalcemia of  
malignancy including parathyroid hormone-related peptide-mediated humoral hypercalcemia, osteolytic metastases-related hypercalcemia, 
1,25 Vitamin D-mediated hypercalcemia, and parathyroid hormone-mediated hypercalcemia in patients with parathyroid carcinoma and 
extra parathyroid cancers. Diagnosis should include the history and physical examination as well as measurement of  the above mediators of  
hypercalcemia. Management includes hydration, calcitonin, bisphosphonates, denosumab, and in certain patients, prednisone and cinacalcet. 
Patients with advanced underlying kidney disease and refractory severe hypercalcemia should be considered for hemodialysis. Hematology 
or oncology and palliative care specialists should be involved early to guide the options of  cancer targeted therapies and help the patients 
and their closed ones with the discussion of  comfort-oriented care.
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Introduction
Hypercalcemia is defined as an increase in the serum 
calcium level above the upper limit of normal for 
a given reference value used in a laboratory.[1] The 
differential diagnosis of hypercalcemia includes multiple 
pathologic entities but is focused primarily on primary 
hyperparathyroidism and hypercalcemia of malignancy 
given the highest prevalence of these etiologies.[1] It 
seems that hypercalcemia of malignancy is a common 
finding in patients with cancer, affecting up to 44.1% of 
patients.[2,3] It is also important to note that hypercalcemia 
of malignancy is particularly common in cases of 
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charts of more than 52,000 patients.[6] The goal of their 
work was to study whether a finding of elevated calcium 
can predate the development of malignancy. Patients 
with hypercalcemia comprised the minority but had 
higher rates of cancer diagnosis at 1-year (6.2% compared 
to 3.0%). However, the retrospective methodology of 
this study should be kept in mind when interpreting 
the study results. Another important aspect to mention 
briefly is that not all hypercalcemia in cancer patients is 
secondary to malignancy, and this is discussed further 
in subsequent sections.[7]
The goal of this study is to review the current knowledge 
on the etiopathogenesis, clinical presentation, diagnosis, 
and treatment of hypercalcemia of malignancy. We 
searched PubMed/Medline, Scopus, Embase, and Web 
of Science for original articles, case reports, and case 
series articles focused on hypercalcemia of malignancy 
published from 1950 to December 2014. The search terms 
were: Hypercalcemia of malignancy, hypercalcemia, 
Vitamin D and hypercalcemia, skeletal metastases 
and hypercalcemia, parathyroid hormone (PTH), 
PTH-related peptide (PTHrP), and the combination 
of these. The reference lists of the identified articles 
were further screened for potentially relevant articles 
that could be overlooked by an electronic search. The 
search methodology was adapted from the scientific 
search guidelines published in 2011.[8] We start with a 
physiological overview of calcium metabolism. Second, 
we discuss the etiology and pathogenesis of hypercalcemia 
of malignancy. Third, we review the clinical presentation 
of hypercalcemia. Fourth, the diagnostic approach to 
hypercalcemia is addressed. Finally, the management of 
hypercalcemia of malignancy is discussed.
Normal Regulation of Calcium Metabolism
Calcium is an essential element that participates 
in various biochemical reactions, including muscle 
contraction, coagulation and bone development among 
others.[9] Calcium is absorbed predominantly in the 
small intestine, and it is necessary to note that only 
10-20% of ingested calcium is absorbed, the remainder 
being excreted with the stool.[9] Calcium in the body 
is present in two major compartments: Bone, where 
calcium is stored as hydroxyapatite salt that comprises 
the major part of body calcium, and plasma.[10] In plasma, 
serum calcium is present in several forms, such as free 
or ionized calcium, which is actually a physiologically 
active form corresponding to approximately 45% of 
serum calcium, with 65% of calcium being bound to 
various carriers, such as albumin (40% of calcium), citric 
acid, sulfate, and phosphate.[10]
Several hormonal systems regulate calcium absorption 
and metabolism. When calcium levels drop below 
10 mg/dl, this activates calcium-sensing cells in the 
parathyroid glands to stimulate the release of PTH. 
PTH release reaches a peak when calcium falls below 
7.5 mg/dl.[9] When the calcium level is above 10 mg/dl, the 
secretion of PTH is minimal. PTH has several important 
actions focused on the increase of serum calcium. 
First, PTH activates the 1-alpha-hydroxylase enzyme 
located in the renal proximal tubules, which in turn 
converts 25-hydroxyvitamin D into the more active 
1,25-dihydroxyvitamin D.[10] Second, PTH stimulates 
calcium reabsorption in the distal part of the nephron 
(thick ascending limb of the loop of Henle and distal 
convoluted tubule) and renal phosphorus excretion. 
Third, PTH leads to calcium mobilization from the bone 
with the help of 1,25-dihydroxyvitamin D. All these 
actions aim to increase calcium concentrations, bringing 
them back to normal.
Another key player in normal calcium metabolism 
is Vitamin D. Vitamin D or cholecalciferol sources 
in the body include synthesis in the skin from 
7-dehydroca lc i fero l  under  the  in f luence  o f 
ultraviolet light and dietary intake.[10] Subsequently, 
25-hydroxycholecalc i ferol  wil l  be  converted 
into 25-dihydroxycholecalciferol in the liver by 
25-hydroxyvitamin D3 1-alpha-hydroxylase . 
Eventually, 25-dihydroxycholecalciferol will be 
delivered into kidneys where it can be activated by the 
aforementioned 1-alpha-hydroxylase enzyme (which is 
activated by PTH) into 1,25-dihydroxycholecalciferol.[10] 
1,25-dihydroxycholecalciferol in turn increases the 
absorption of calcium and phosphate in the gastrointestinal 
tract, decreases the renal excretion of calcium and 
phosphate, and with the participation of PTH leads 
to increased calcium release from the bone and 
subsequent bone mineralization.[9] It is important to 
note that 1,25-dihydroxycholecalciferol is deactivated 
by the 24,25-hydroxylase enzyme in the kidneys.[10]
From a normal physiology perspective, it is important 
to mention a thyroid hormone, calcitonin, which is 
produced by thyroid C cells.[10] Calcitonin release is 
augmented when calcium concentration increases and 
limits bone remodeling and subsequent calcium release 
from the bone and calcium reabsorption in the kidneys. 
However, tumors secreting calcitonin, such as medullary 
thyroid cancer, do not lead to low calcium levels.[10] 
Nevertheless, calcitonin may be used in the management 
of hypercalcemia of malignancy (as discussed below). 
A possible explanation for the efficacy of calcitonin in 
patients with malignancy-related hypercalcemia could 
be related to secondary overzealous bone resorption and 
calcium release in these patients.
Finally, it is necessary to discuss briefly the different roles 
of major bone cells and their interplay in bone turnover 
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and calcium release. For this purpose, we focus on two 
cellular types: Osteoblasts and osteoclasts. Osteoblasts 
derive from mesenchymal cells and osteoclasts originate 
from monocyte lineage that migrates into the bone 
environment from the bloodstream.[10,11] Osteoclast 
precursor cells carry the receptor activator of nuclear 
factor-κ B (RANK).[10,11] Osteoblasts in turn secrete 
a ligand for RANK (RANKL), which stimulates the 
maturation of osteoclast precursors and the formation 
of mature osteoclasts capable of bone remodeling 
and calcium release.[11,12] Factors that promote bone 
remodeling and calcium release from the bone stimulate 
osteoblasts through RANKL release and subsequent 
activation of osteoclasts. Factors that exert the opposite 
effects on bone turnover (such as estrogens) stimulate 
the release of osteoprotegerin from osteoblasts, binding 
RANKL, and preventing it from binding to RANK on 
the osteoclast precursor cell.[12-14]
In conclusion, the intricate interaction between calcium 
levels, PTH, Vitamin D, and bone cells regulates bone 
metabolism and calcium release from the bones.
Etiology and Pathobiology of Hypercalcemia 
of Malignancy
There are several major mechanisms of hypercalcemia 
of malignancy, which are discussed here. First, the 
major mechanism, accounting for approximately 80% of 
malignancy-related hypercalcemia, is mediated by the 
production of PTHrP.[4] It is also important to note that 
PTHrP is normally produced and secreted by various 
cells, and normal breast cells in particular.[15] Furthermore, 
PTHrP under normal physiological conditions 
participates in the development of various tissues, 
facilitates transplacental calcium transport, and promotes 
calcium transfer to breast milk.[15] Both PTH and PTHrP 
act on the same receptors and their effects consistently 
overlap. Indeed, the biochemical structure of PTHrP 
greatly resembles that of PTH.[15] However, PTHrP does 
not seem to have a major influence on the production 
of 1,25-dihydroxycholecalciferol.[15] Therefore, PTHrP 
acts on osteoblasts, leading to enhanced synthesis of 
RANKL, with subsequent activation of osteoclasts 
and bone resorption with calcium release into the 
bloodstream. Increased renal calcium reabsorption is 
another mechanism through which PTHrP leads to 
hypercalcemia. Squamous cell cancers, urinary tract 
cancers (renal cancer and bladder cancer), breast cancer, 
nonHodgkin’s lymphoma, and ovarian cancer account 
for the majority of malignancies leading to hypercalcemia 
via PTHrP.[4]
The second mechanism by which malignancies cause 
hypercalcemia includes osteolytic metastases and 
excessive calcium release from bone, accounting 
for approximately 20% of malignancy-related 
hypercalcemia.[4] Breast cancer and multiple myeloma 
account for the vast majority of the cases of osteolytic 
hypercalcemia.[4] It is interesting to note that metastatic 
breast cancer cells may produce PTHrP locally, without 
a major increase in serum PTHrP.[16] Local factors that are 
released in the presence of metastatic bone lesions include 
transforming growth factor β, which stimulates PTHrP to 
be produced locally from metastatic breast cancer cells.[17] 
In turn, the elevation of calcium further stimulates local 
PTHrP release, generating a vicious cycle. In the case of 
multiple myeloma, the local release of various cytokines, 
such as RANKL, interleukin-3 and -6, facilitate bone 
remodeling and resultant hypercalcemia.[18] It is worth 
noting that a very small proportion of patients with 
multiple myeloma and hypercalcemia do not have true 
hypercalcemia.[19] This apparent increase in calcium is 
mediated by calcium binding to paraprotein secreted 
by multiple myeloma cells.[19] It should be borne in mind 
that such patients will typically have a mild elevation 
in total calcium with normal ionized levels and will not 
have any symptoms of hypercalcemia.
The third mechanism includes ectopic activity of 
1 -a lpha-hydroxy lase  and  the  format ion  o f 
1,25-dihydroxycholecalciferol, common in lymphomas 
and in some ovarian germ cell tumors.[4] The fourth 
mechanism by which cancer can lead to hypercalcemia 
includes ectopic production of PTH,[20] or in rare cases 
PTH can be secreted by parathyroid carcinoma.[21] Small 
cell lung cancer and adenocarcinoma can mediate 
hypercalcemia via such mechanism.[20] Furthermore, it 
is important to note that some patients with apparent 
hypercalcemia of malignancy will have evidence of 
primary hyperparathyroidism.[22-24]
In conclusion, there are several major mechanisms that 
account for malignancy-related hypercalcemia, including 
the excessive tumor production of PTHrP, osteolytic 
metastatic disease, ectopic activity of 1-alpha-hydroxylase 
and the production of 1,25-dihydroxycholecalciferol, the 
excessive production of PTH by parathyroid carcinoma 
and extra parathyroid malignancies, and finally 
hypercalcemia due to paraprotein binding. The major 
mechanisms of malignancy-related hypercalcemia are 
emphasized in Figure 1.
Clinical Presentation of Hypercalcemia
For a long time, clinicians used mnemonics, such as 
“stones, bones, abdominal moans, and psychic groans” 
to memorize the major clinical manifestations of 
hypercalcemia.[4] Indeed, the major systems affected by 
hypercalcemia include neuropsychiatric, gastrointestinal, 
and renal. It is important to note that at least two factors 
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play a role in the development of clinically overt 
hypercalcemia, such as the degree of hypercalcemia 
and the rapidity of its development. Patients with 
hypercalcemia of malignancy typically have a higher 
degree of hypercalcemia and develop it over a shorter 
period, which is why these patients are usually more 
symptomatic than patients with other etiologies of 
hypercalcemia.[4]
Neurocognitive symptoms of hypercalcemia may 
include some behavioral disturbances, such as anxiety, 
mood changes and a decrease in cognitive function, 
which are typical of milder cases of hypercalcemia 
(degrees of hypercalcemia are discussed further in 
the next section). However, as patients with cancer 
generally present with higher values of calcium, they 
may develop more severe presentations, such as changes 
in mental status, including coma.[25] Furthermore, 
patients with malignancy-related hypercalcemia 
may develop a syndrome of posterior reversible 
leukoencephalopathy (PRES), which is characterized 
clinically by the development of headaches, seizures 
and imaging findings of subcortical edema.[26,27] Several 
pathobiological factors such as cerebral vasoconstriction, 
endothelial dysfunction, and systemic inflammation may 
precipitate PRES in such groups of patients.[27]
Renal manifestations of hypercalcemia consist of 
nephrogenic diabetes insipidus with resultant polyuria, 
renal vasoconstriction, distal renal tubular acidosis, 
and in more chronic cases, nephrolithiasis, tubular 
dysfunction, and chronic renal failure.[28,29]
Elevated calcium levels also affect the gastrointestinal 
system. Mild elevation of calcium may present as 
anorexia and constipation.[1] Patients with more advanced 
hypercalcemia may develop nausea and vomiting. 
Thus, all patients with clinically overt hypercalcemia 
are volume depleted, which is explained by the renal 
effects of hypercalcemia (polyuria) and the decreased 
oral intake with associated nausea and vomiting. Other 
possible gastrointestinal manifestations of hypercalcemia 
include pancreatitis and peptic ulcer disease.[30,31] 
However, it is important to note that peptic ulcer disease 
has predominantly been reported in hypercalcemia 
due to primary hyperparathyroidism.[30] Nevertheless, 
clinicians should bear in mind this potential complication 
in a patient with hypercalcemia and clinical findings 
suggestive of upper gastrointestinal bleeding (such as 
black tarry stools or frank bloody stools, epigastric pain, 
dropping hematocrit, and hemodynamic instability).
Another organ system that may be affected by elevated 
calcium is the cardiovascular system. Patients with 
hypercalcemia typically have a shortened QT interval on 
the electrocardiogram (ECG).[32] Severe hypercalcemia 
may mimic ST-segment elevation myocardial infarction 
on the ECG.[33-35] Cardiac catheterization has been 
found to be negative for coronary atherosclerosis[32,33] 
and in one case, myocardial infarction has been ruled 
out with serial cardiac enzymes (troponin and creatine 
kinase-MB fraction) measurements.[34] Furthermore, 
patients with severe hypercalcemia may develop 
malignant ventricular arrhythmias such as ventricular 
fibrillation.[36]
Also, it is important to bear in mind that most patients 
with malignancy-related hypercalcemia have clinically 
overt cancer (either retrospectively or newly diagnosed). 
Therefore, in a patient without documented malignancy 
but with severe newly diagnosed hypercalcemia, it 
is important to take a focused history (e.g., smoking 
history, exposure to carcinogens, family history of 
cancer, prior personal history of cancer, presence of 
cough, unintentional weight loss, etc.), and perform 
a thorough physical examination (e.g., breast mass in 
a female patient, abdominal mass on palpation, etc.) 
in order to guide a further diagnostic work-up. A 
summary of the clinical features of hypercalcemia is 
presented in Table 1.
Table 1: Clinical features of hypercalcemia
Organ system Clinical features
Neurologic Fatigue, altered mental status 
including coma, posterior reversible 
leukoencephalopathy
Gastrointestinal Nausea, vomiting, constipation, peptic ulcer 
disease, and pancreatitis
Cardiovascular Short QT interval on ECG, ST segment 
abnormalities including ST segment 
myocardial infarction mimic, malignant 
ventricular arrhythmias, and hypertension
Renal Nephrogenic diabetes insipidus, acute 
kidney injury
ECG = Electrocardiogram
Figure 1: Etiobiology of hypercalcemia of malignancy
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Diagnostic Approach to Hypercalcemia
As discussed above, serum calcium is the sum of 
carrier-bound calcium that is not physiologically active 
and ionized calcium, which is the active form of serum 
calcium.[9] Thus, when evaluating elevated serum calcium 
levels, it is essential to keep this in mind, especially as 
most general chemistry tests measure total calcium 
rather than free ionized calcium. Therefore, conditions in 
which the alteration of serum protein levels is a feature 
may have abnormal total calcium levels, but may not 
have any changes in physiologically important ionized 
calcium levels.[37] For example, malnourished patients or 
patients with a protein-losing condition (e.g., nephrotic 
syndrome, protein-losing enteropathy, etc.) may be 
found to have low total calcium levels due to a decrease 
in albumin levels, a major carrier for calcium in the blood 
(it is possible that some patients with low total calcium 
may have elevated ionized calcium due to underlying 
conditions such as cancer). On the other hand, patients 
with severe dehydration may have elevated protein 
levels and hence, elevated calcium levels.[37]
Therefore, it is advised to confirm elevated serum 
calcium with a repeat test. Nevertheless, it is reasonable 
to start treatment with intravenous (IV) fluid hydration 
for markedly elevated calcium levels, especially with 
associated typical symptoms, while awaiting a repeat 
calcium measurement. Several approaches can be 
used to distinguish between true hypercalcemia and 
pseudohypercalcemia. First, it is possible to estimate 
the levels of free or ionized calcium after adjustment 
for albumin levels. Correction of calcium for albumin 
level should be done in patients with abnormal (both 
low and elevated levels) albumin and can be calculated 
via this formula: Calcium (mg/dl) + 0.8 (4.0 − patient’s 
albumin level); however, numerous free online 
calculators are available which can be used in clinical 
practice. Second, it is possible to measure ionized 
calcium levels directly, and this may be the preferred 
method given its higher sensitivity, as albumin is the 
major but not the only carrier.[38] Most laboratories 
in the United States of America use a range of total 
serum calcium levels of 8.5-10.2 mg/dl (please follow 
your institution’s range for serum calcium). We divide 
hypercalcemia into mild hypercalcemia with serum 
calcium levels <12 mg/dl, moderate hypercalcemia with 
serum calcium levels between 12 mg/dl and 14 mg/dl, 
and severe hypercalcemia with serum calcium levels 
above 14 mg/dl.
From a clinical perspective, most cases of hypercalcemia 
are due to cancer or primary hyperparathyroidism.[1,37] 
However, as already discussed, most patients with 
cancer have greater levels of calcium than patients with 
hypercalcemia secondary to other causes and are more 
symptomatic. Furthermore, the diagnosis of cancer will 
be obvious in a great number of cases. Nevertheless, 
from the conceptual perspective, hypercalcemia can be 
divided into PTH-dependent and PTH-independent 
(after confirmation of truly elevated calcium).[1,37] 
PTH-dependent causes largely include primary 
hyperparathyroidism, PTH production by malignant 
cells (parathyroid carcinoma and extra parathyroid 
cancers) and familial hypocalciuric hypercalcemia.[1,37] 
Other causes of hypercalcemia (including cancer-related) 
constitute PTH-independent hypercalcemia.
The next step in evaluating a case with suspicious 
features of malignancy-related hypercalcemia consists 
of measuring both PTH and PTHrP. The reason for the 
PTH measurement in such cases includes the fact that 
patients with cancer may have a greater prevalence 
of primary hyperparathyroidism, and some patients 
with cancer may have primary hyperparathyroidism 
as a sole cause of hypercalcemia.[7,22,39] In cases in which 
malignancy is the only cause of hypercalcemia, serum 
PTH levels should be suppressed or low normal. High 
normal PTH levels in the setting of hypercalcemia are 
inappropriate and suggest the presence of parathyroid 
hyperfunction.[1,37] Given the fact that some cancers may 
produce PTH ectopically,[20,40] imaging tests may be used 
to evaluate the parathyroid glands for hyperfunction in 
selected cases.[41,42] PTHrP levels will be elevated in cases 
of humoral hypercalcemia of malignancy. However, 
in some cases, in which the diagnosis of cancer (e.g., 
known advanced squamous cell carcinoma of the 
lung) is well known, the measurement of PTHrp levels 
may be omitted. From a management perspective, the 
degree of PTHrP elevation may predict response to 
bisphosphonates and mortality.[43-46]
If the PTHrP levels are low, the next step should include 
measurement of 1,25-dihydroxyvitamin D levels to 
screen for Vitamin D-mediated hypercalcemia, which is 
typically seen in lymphomas. In patients with low levels 
of PTH, PTHrp, and 1,25-dihydroxyvitamin D, one might 
consider hypercalcemia due to osteolytic metastases 
as the cause of malignancy-related hypercalcemia. 
However, it is important to note that more than one 
mechanism of malignancy-associated hypercalcemia can 
be seen in a particular patient.[47]
Furthermore, an approach to hypercalcemia should be 
thorough and include the review of medications.[1,37] 
Medications such as lithium, thiazide diuretics, and 
Vitamin A and D supplements should be discontinued 
if possible. These medications might not explain the 
hypercalcemia, but have the potential to make it worse.
In conclusion, an approach to hypercalcemia consists 
of confirming that hypercalcemia is true. Second, 
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measurements of PTH and PTHrp should start the 
laboratory work-up. Serum 1,25-dihydroxyvitamin D 
measurement should be undertaken when OTH and 
PTHrp are decreased. Hypercalcemia secondary to 
osteolytic metastases should be considered when the 
laboratory values mentioned above are decreased. 
Furthermore, a review of home medications should be 
done and the discontinuation of medications capable 
of causing hypercalcemia should be considered. 
A diagnostic flowchart is presented in Figure 2.
Management of Hypercalcemia
The management of hypercalcemia is based on the 
presence of characteristic symptomatology and the 
severity of calcium elevation. Patients with hypercalcemia 
of malignancy are typically symptomatic and have 
markedly elevated calcium levels. Thus, patients with 
hypercalcemia will generally need to be managed with 
urgency, and hypercalcemia of malignancy in many cases 
represents an oncologic emergency.
The treatment options for hypercalcemia include IV 
hydration, calcitonin, bisphosphonates, denosumab, 
gallium nitrate, prednisone, and hemodialysis. Each 
therapeutic modality is discussed in greater detail 
in this section. It is also important to emphasize that 
given the overall poor prognosis of many patients with 
malignancy-related hypercalcemia, a palliative care 
team should be involved in the care of the patient and 
the goals of care should be discussed with the patient or 
his or her surrogate.
As discussed above, patients with hypercalcemia 
are dehydrated by default due to poor oral intake 
secondary to nausea, vomiting, altered mental status, and 
hypercalcemia-induced nephrogenic diabetes insipidus. 
Furthermore, volume contraction in itself compromises 
renal clearance of calcium due to hypovolemia-mediated 
increased calcium reabsorption in the kidneys.[47] Several 
factors, such as the presence of underlying cardiorenal 
disease, should be borne in mind when considering IV 
hydration. Isotonic crystalloid solutions (e.g., normal 
saline) should be used for IV hydration.[48] We typically 
start patients with advanced hypercalcemia at a rate of 
around 200-300 ml/h and reassess them periodically 
for signs of fluid overload (shortness of breath, edema, 
etc.). The rate of IV hydration should be decreased in 
patients with underlying cardiac and renal disease to 
minimize the risk of symptomatic fluid overload. It 
is important to mention that the routine use of loop 
diuretics such as furosemide is not recommended due 
to the development of volume depletion and electrolyte 
abnormalities.[49] Moreover, there are much more specific 
therapies targeting hypercalcemia. The use of furosemide 
should be reserved for patients who develop signs of 
fluid overload while receiving IV hydration.
However, IV hydration alone is not enough to correct 
severe hypercalcemia. The second option that should be 
considered in the management of severe hypercalcemia 
is calcitonin.[50] It is important to emphasize that only 
intramuscular or subcutaneous administration should 
be used given the fact that intranasal calcitonin does 
not seem to be effective in hypercalcemia for reasons 
that are not yet clear.[51] The typical dose of calcitonin for 
the management of hypercalcemia ranges from 4 IU/kg 
to 8 IU/kg.[50,52] The drop in serum calcium typically 
occurs within 4 h after administration and one should 
expect a maximal drop in calcium of 2 mg/dl.[50,52] The 
dosing intervals range from every 6 h to every 12 h. It is 
important to note that both the dose and administration 
frequency are tailored to the hypocalcemic response. 
The duration of administration is typically limited 
to 48 h given the development of tachyphylaxis and 
decreased responsiveness.[50,52] Calcitonin seems to work 
via the inhibition of osteoclast activity and an increase 
in renal calcium excretion.[53] Calcitonin is an important 
adjunctive medication in the management of severe 
hypercalcemia given its rapid onset of action and serves 
as a bridge while other treatment modalities are reaching 
its therapeutic effect.
Bisphosphonates comprise a group of medications 
that are analogs of natural pyrophosphate, which is 
an essential part of bones.[54,55] Bisphosphonates are 
used in many situations, such as the treatment and 
prevention of osteoporosis, Paget’s disease of bone, 
metastatic bone disease, and hypercalcemia. This 
section discusses the use of bisphosphonates in the 
management of symptomatic hypercalcemia, particularly 
hypercalcemia of malignancy. For greater detail on the 
role of bisphosphonates in the management of other Figure 2: Diagnostic flowchart on the work up of hypercalcemia
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diseases, the reader is referred to review articles on this 
topic.[54,55] Bisphosphonates are typically subdivided into 
two groups: First generation and second-generation. 
The first-generation or nonnitrogen-containing 
bisphosphonates include etidronate and clodronate, 
which are less commonly used nowadays.[54,55] The second-
generation or nitrogen-containing bisphosphonates 
include such medications as alendronate, risedronate, 
ibandronate, pamidronate, and zoledronic acid, which 
are generally more potent than the first-generation 
bisphosphonates. The mechanisms of action include the 
impairment of osteoclast-mediated bone resorption, the 
arrest of osteoclast development, osteoclast apoptosis, 
and a decrease in osteoblast apoptosis.[54,55]
Zoledronic acid, ibadronate, pamidronate, and less often 
etidronate are used for the treatment of hypercalcemia 
of malignancy. Zoledronic acid is the most potent 
agent among the bisphosphonates, as shown in a study 
that compared zoledronic acid to pamidronate.[56] The 
typical dose is 4 mg administered IV over 15-30 min. 
Pamidronate and ibandronate are less potent agents 
than zoledronic acid but have similar efficacy when 
compared to each other.[57] The typical dose range for 
pamidronate is from 60 mg to 90 mg administered 
IV over 2 to 24 h. However, a shorter duration of 
pamidronate administration, such as 4 h, may be as safe 
as the longer duration of administration.[58] Ibandronate 
has a dose range from 2 mg to 6 mg administered IV, 
but it is important to mention that the use of ibandronate 
is off-label for the treatment of hypercalcemia.[57] These 
drugs have been used in patients with underlying kidney 
dysfunction and hypercalcemia of malignancy. For 
example, zoledronic acid has been used in patients with 
creatinine of 4.5 mg/dl[56] and pamidronate in patients 
with creatinine of 1.5 mg/dl and higher.[59] Nevertheless, 
it is advised to decrease the doses and duration of 
administration in patients with underlying renal disease. 
However, bisphosphonates seem to be safe in patients 
with end-stage renal disease on hemodialysis.[60,61] The 
onset of the calcium-lowering effect is within 2-4 days 
after the administration.
Bisphosphonates are usually well-tolerated, but several 
classic side effects have been described. Patients taking 
bisphosphonates commonly experience flu-like symptoms; 
other potential side effects include ocular symptoms, acute 
kidney injury, new-onset nephrotic syndrome, esophageal 
inflammation (typically for orally administered drugs), 
and very rarely osteonecrosis of the jaw.[54,55] Osteonecrosis 
of the jaw is typically reported in patients with multiple 
myeloma or metastatic bone disease receiving high potency 
bisphosphonates, such as zoledronic acid and denosumab, 
which is a monoclonal antibody to RANKL.[62] However, 
patients who develop this complication typically receive 
the aforementioned medications for at least 4 months. Thus, 
osteonecrosis of the jaw is not typically a problem during 
acute management of hypercalcemia of malignancy. It 
is important to mention that bisphosphonates are given 
once, and the dose should be repeated no earlier than 
1-week after the administration of the first dose. Moreover, 
as mentioned above, patients with marked elevation of 
PTHrP may be more resistant to the hypocalcemic effects 
of bisphosphonates.[43-46]
Denosumab is a human monoclonal antibody to 
RANKL, thus working through decreasing osteoclast 
activity and bone resorption.[63] Denosumab has been 
shown to be effective in hypercalcemia refractory to 
bisphosphonates.[21,64-66] Furthermore, denosumab has an 
advantage to bisphosphonates in that it is not removed by 
the kidneys. It is important to mention that denosumab 
has been shown to improve renal function in patients 
with multiple myeloma and hypercalcemia.[67,68] However, 
the effect of denosumab may be more pronounced in 
patients with renal failure, and some have suggested 
a lower dose (half) in the case of renal failure.[68] The 
typical dose of denosumab is 120 mg subcutaneously, 
and the dose should be repeated no earlier than 1-week 
following the first administration.[69] The hypocalcemic 
effect of denosumab is typically seen within 2-4 days 
after the administration. The use of denosumab for the 
management of hypercalcemia of malignancy is off-label 
and should be reserved for cases of severe hypercalcemia 
refractory to more conventional treatment.
Common side effects attributed to denosumab include 
bone pain, nausea, diarrhea, shortness of breath, and in 
rare instances osteonecrosis of the jaw, which is usually 
seen in patients treated with denosumab for at least 
several months, thus making it less important in the 
acute setting of hypercalcemia of malignancy.[62,63] Data 
on denosumab and infectious risk are controversial, but 
a major clinical study failed to demonstrate an infectious 
risk in patients treated with denosumab.[70]
Patients with lymphomas and some ovarian germ tumors 
who overproduce 1,25-dihydroxycholecalciferol can be 
treated with prednisone to reduce the gastrointestinal 
absorption of calcium.[71] The typical dose of prednisone 
is 20-40 mg orally.[71] Common side effects of prednisone 
use include hyperglycemia, hypertension, psychiatric 
disturbances, muscle weakness, peptic ulcer disease, 
and many others.[72]
Other pharmacological options for the treatment of 
hypercalcemia include cinacalcet and gallium nitrate. 
Cinacalcet works by decreasing the production of 
PTH[73] and is commonly used in the management of 
hypercalcemia secondary to parathyroid carcinoma.[73,74] 
It is unclear whether it can be used in a rare extra 
parathyroid cancer patient with ectopic production of 
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PTH. The typical dose range of cinacalcet is from 60 mg to 
360 mg orally, and the dose is typically split throughout 
the day. Common side effects include nausea, vomiting, 
and headaches.
Lastly, gallium nitrate can be used in the treatment of 
malignancy-related hypercalcemia via the inhibition of 
osteoclast activity and by increasing the renal calcium 
clearance.[75-77] The typical dose used in the clinical studies 
is 200 mg/m2 administered as a slow IV infusion daily for 
5 days.[78,79] Gallium nitrate has been shown to be more 
potent than calcitonin, notably in a study of 164 patients 
with cancer-related hypercalcemia.[78] The medication was 
well tolerated with a small percentage of treatment-related 
anemia and acute kidney injury being observed.[78,79] 
However, gallium nitrate production was discontinued 
by the manufacturer in 2012, making it unavailable for the 
treatment of malignancy-related hypercalcemia.
Finally, patients with refractory severe hypercalcemia 
and underlying cardiorenal diseases that cannot safely 
be hydrated should be considered for hemodialysis.[80,81] 
It is also important to consult with a hematologist or 
oncologist regarding the cancer-targeted treatment 
options for every patient, and a palliative care 
professional to improve the patient’s symptoms and 
explore comfort care options in the right clinical 
scenario.
In conclusion, the treatment of symptomatic 
malignancy-related hypercalcemia should start with 
aggressive IV hydration in patients without significant 
renal or cardiac disease. Calcitonin can be used given 
its prompt effect and favorable side-effect profile. 
Bisphosphonates should be administered concurrently as 
the hypocalcemic effect starts within 2-4 days. Prednisone 
can be used in patients with an overproduction of 
1,25-dihydroxycholecalciferol and cinacalcet should be 
considered in patients with an overproduction of PTH 
(e.g., parathyroid carcinoma). Patients with refractory 
hypercalcemia should be considered for denosumab 
therapy and lastly for hemodialysis. A summary of the 
therapeutic options for the treatment of hypercalcemia 
is presented in Table 2.
Table 2: Summary of pharmacologic therapeutic options for the management of hypercalcemia
Agent Typical dose Mechanism of 
action
Modification based on 
underlying renal and 
liver disease
Onset of action Common side 
effects
Normal saline 200-300 milliners/
hour, lower rate 
in patients with 
underlying cardiac 
and kidney disease
Volume 
repletion, 
increased renal 
calcium clearance
Consider lower rate in 
patients with underlying 
renal disease
Within hours of 
administration
Volume overload, 
non-anion 
gap metabolic 
acidosis
Calcitonin 4-8 international 
units/kg 
subcutaneously or 
intramuscularly
Inhibition of 
osteoclast activity 
and increase in 
renal calcium 
clearance
No dosage adjustment is 
needed
Within 4 h of 
administration. 
Tachyphylaxis 
develops after 48 h
Nausea, rhinitis, 
hypersensitivity 
reactions
Bisphosphonates Zoledronic acid 4 
mg administered 
IV over 15 min; 
pamidronate 60-90 
mg administered 
IV over 2-24 h; 
ibandronate 2-6 mg 
administered IV 
over 1-2 h
Inhibition 
of osteoclast 
acitivity, 
osteoclast 
apoptosis and 
improved 
osteoblast 
survival
Zoledronic acid: Do not use 
in patients with creatinine 
>4.5 mg/dl (consider 
increasing the infusion 
duration in patients with 
kidney disease); no need 
for hepatic adjustment
Pamidronate and 
ibandronate: Do not use if 
glomerular filtration rate 
is <30; no need for hepatic 
adjustment
Within 2-4 days 
after administration. 
Do not repeat 
administration 
earlier than 1 week 
after the previous 
IV infusion
Flu-like 
symptoms, bone 
aches, nephrotic 
syndrome, acute 
kidney injury, 
osteonecrosis of 
the jaw
Denosumab 120 mg 
subcutaneously
Impairs 
osteoclast activity
No need for renal and 
hepatic adjustment. 
Consider half dose for 
patients with renal disease 
to decrease the risk of 
hypocalcemia
Within 2-4 days 
after administration. 
Do not repeat 
administration 
earlier than 1 week 
after the previous 
dosing
Bone pain, 
nausea, diarrhea, 
shortness 
of breath, 
osteonecrosis 
of the jaw and 
possibly increase 
in the risk of 
infections after 
long-term use
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Conclusion
Hypercalcemia of malignancy is a common finding 
typically in patients with advanced stage cancers. 
Hypercalcemia of malignancy usually presents with 
markedly elevated calcium levels and patients are 
therefore usually severely symptomatic. Several major 
mechanisms are responsible for the development of 
hypercalcemia of malignancy, including PTHrP-mediated 
humoral hypercalcemia, osteolytic metastases-related 
hypercalcemia, 1,25-dihydroxyvitamin D mediated-
hypercalcemia, and PTH-mediated hypercalcemia 
in patients with parathyroid carcinoma and extra 
parathyroid cancers. Diagnosis should include the 
history of the patient and physical examination, as 
well as the measurement of the above mediators of 
hypercalcemia. Management includes IV hydration, 
calcitonin, bisphosphonates, denosumab, and prednisone 
and cinacalcet in certain patients. Patients with advanced 
underlying kidney disease and refractory severe 
hypercalcemia should be considered for hemodialysis. 
Hematology or oncology and palliative care specialists 
should be involved early on to guide the selection of 
cancer-targeted therapies and help the patients and 
surrogates with comfort care and discussing potential 
comfort care options.
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